
@2025 Afarand., IRAN
ISSN: 2251-8215 Sarem Journal of Reproductive Medicine 2017;1(4):165-169
ISSN: 2251-8215 Sarem Journal of Reproductive Medicine 2017;1(4):165-169
Genotyping of Human Papillomavirus in Cervical Liquid-Based Cytology Specimens
ARTICLE INFO
Article Type
Original ResearchAuthors
Rezaei S. (1)Saadatniya G. (*)
Salehian P. (2)
(*) Department of Biotechnology,Iranian Research Organization for Science and Technology (IROST), Tehran, Iran
(1) Sarem Cell Research Center (SCRC), Sarem Women’s Hospital, Tehran, Iran
(2) Sarem Fertility & Infertility Research Center (SAFIR), Sarem Women’s Hospital, Tehran, Iran
Correspondence
Article History
Received: April 29, 2016Accepted: October 11, 2016
ePublished: November 15, 2017
BRIEF TEXT
Cervical cancer is the second most common cancer in women, with an annual incidence of around half a million people worldwide, leading to death in at least 50% of cases [1-3]. ... [4]. Human papillomavirus (HPV) is known to be one of the most important causes of cervical cancer [5].
... [5-7]. Human papillomavirus is a small, uncoated virus with a double-stranded DNA that has at least 100 different types [8]. Approximately 35 to 40 types of this virus infect epithelium of the skin or mucous membrane in the female reproductive system [9, 10]. Most viral infections produce a specific, undigested symptom and are spontaneously improved [8]. If the infection continues, because of the high incidence of lesions in the virus and the self-limiting blemishes of the skin that often appear on the palms and legs, malignant and invasive lesions appear to be a cervical cancer. Condyloma acuminatum (anogenital warts) is one of the most commonly reported viral diseases transmitted through sexual contact [8-11]. Mucosal types can be classified as high-risk and low-risk depending on the risk of the disease. Harmful types of human papillomavirus play a major role in the development of cervical cancer [9]. Of these viruses, at least 15 types of high-risk viruses cause more than 95% cervical cancer and 80% vaginal cancer [1, 12]. Therefore, accurate diagnosis will have a significant impact on the control and management of this cancer and promote the health of women in the community [13]. Currently, 118 HPV genotypes are categorized according to the type of biological wall and oncogenicity and type of racial evolution. Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 are known as high risk [14]. Types 26, 53, and 66 may have oncogenic properties [15]. An abnormal epithelial cells of the cervix can be detected by staining a pap smear and observing it under a microscope, but this diagnosis only applies to women with advanced disease risk, and about 50% of lesions are not detected by Pap smear alone. Since the HPV virus does not grow in the culture medium and serologic testing has limited accuracy (HPV infection produces a humoral immune response against a capsid protein that remains antibodies for many years), serological tests are not appropriate for the diagnosis of present and past infections [16]. As a result, the exact diagnosis of HPV infection depends mainly on the molecular method. Molecular techniques can be used to detect and accurately identify HPV, as well as to inform the patient and follow up after treatment [17].
This study was conducted to determine genotypes of human papillomavirus in cervical fluid cytology.
This research is descriptive-cross sectional.
This study was carried out on cervical cytology samples from patients aged 25-50 years who referred to Sarem hospital during one year from 2013 to 2014 who were diagnosed with papillomavirus and confirmed by pathological and molecular studies.
42 cytological samples of cervical fluid were studied. Criteria for entering the research included women aged 25 to 50, satisfaction to participate in research, recruitment and confirmation of papillomavirus infection by clinical and pathological examinations based on ICD-9.
Extracting DNA from samples was done using the High Pure PCR Template Preparation Kit (Roche). Genotyping was performed on all HPV positive specimens using the HPV type 3.5 LCD Array (Chipron GmbH, Berlin). In this method, a mixture of pre-labeled primers provided by the kit produces labeled DNA viral compositions. The non-florescent labeled PCR parts are bonded to the dedicated probes attached to the chips bottom with a hybridization buffer, and after washing the chips, the labeled solution is poured onto them, and then the PCR components attached to the labels are seen by the enzyme-substrate reaction in the form of blue spots. Data readout is done both by the scanner and by comparison with the proposed model contained in the kit. In this method, two pairs of primers were provided for PCR, a pair of primers MY09 / MY11 that are commonly used, and the second pair, which produces a piece of 125 buffer pairs. Based on the instructions of the kit, 5 μl of the two independent PCR products were mixed and used to continue hybridization. By using the method used, 32 different types of HPV were identified that included 6, 11, 16, 18, 31, 35, 33, 39, 42, 44, 45, 51, 52, 56, 58, 59, 61, 62, 66, 67, 68, 70, 72, 73, 81, 82, 84, 90 and 91.
Of the 42 LBC samples, 27 cases (64%) belonged to the high-risk group of the papillomavirus. Of these 27 samples, 14 cases (52%) had infections and 70.4% of the samples showed infections of type 16 and 18. The most common type of HPV observed in samples was typed 16 with an abundance of 52%, followed by typing 18 with 18.5%, typing 56, 58 and 66 each with a frequency of 11% and types 31 and 33 with a frequency of 3.7%. Infection with different types of types was observed in 14 cases (52%). In most cases, there were samples of type 16 infections.
... [18, 19]. Currently, vaccines against two types of HPV16 and HPV18 have been approved and used in many countries [20, 21]. International epidemiological studies have shown that HPV16 and HPV18 are high-risk HPV viruses and are seen as isolated and multi-viral infections in at least 75% of cervical cancers [2]. The two viruses also account for 80% of vaginal and vulvar cancers, 92% of anal cancers, 95% of oral cancers and 89% of throat cancer [12]. Six other types of virus (including 31, 33, 35, 45, 52 and 58) cause 19% of cervical cancer, of which two types 45 and 31 are more likely to be detected than the rest and are seen in 10% of cancers [2]. John hu et al., in their study of the effect of papilloma virus genotype on the severity and prognosis of cervical neoplasia in patients, have shown that the type of virus also affects the severity of the disease. In this study, it was stated that the spread of the cancerous area in the HPV types was significantly different and the highest was related to type 18. Therefore, patients with cervical neoplasia with type 18 should be more carefully monitored than patients with other genotypes [22]. In the current study, Type 18 was the second most common type of virus in the study population with a frequency of 18.5%. In Iran, a study by Mahmoudi et al. to determine genotypes of human papillomavirus virus on cervical cancer samples in Yazd province, the HPV genome was identified in 70% of the samples that types 16 and 18 with the frequency of 70% and 16.7% respectively, were the most abundant genotype and other identified types were 33, 45 and 73 [23]. In the study of the prevalence of human papillomavirus in 18-60 year-old married women with natural Pap smear referring to gynecologic clinics of Isfahan University of Medical Sciences, in 46 HPV positive cases, there were type 16 in 15.18% (7 samples), type 18 in 13.4% (6 samples) and type 11 or 6 in 21.74% (6 samples) [24]. Compared to the recent research, Type 16 has been much less prevalent. In a comprehensive study of genotyping of 20,000 Pap smear genotypes in Kerman, 93.75% of HPV-positive people were diagnosed with type 16 and type18 was found only in 6.25% of them [25]. In another study, in which Khoda karami et al. reviewed the prevalence of this infection in the areas of Tehran, the prevalence of HPV was 7.8%, of which 5.1% was high risk [26].
According to various studies in this domain, it is suggested that by implementing a comprehensive epidemiological plan in the country, the actual outbreak of the papillomavirus infection be determined, and this be planned for prevention and control of this disease. It is also suggested that in further research, the demographic, epidemiological and risk factors of the disease be investigated.
Various types of HPV have been identified and the most common type is HPV16. Simultaneous infections with several types of human papillomavirus are common in cervical cytological fluid samples of positive people.
CITIATION LINKS
[1]Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine, 2006;24(3: S3):11-25.
[2]Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs. 2008;68(3):359-72.
[3]Frazer IH. Development and implementation of papillomavirus prophylactic vaccines. J Immunol. 2014;192(9):4007-11.
[4]Human papillomavirus (HPV) and cervical cancer [internet]. World Health Organization: Comprehensive cervical cancer control: A guide to essential practice. 2014. [updated 2016 Jun; cited 2015 apr]. Available from: http://www.who.int/mediacentre/factsheets/fs380/en/.
[5]Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.
[6]Franco EL, Harper DM. Vaccination against human papillomavirus infection: A new paradigm in cervical cancer control. Vaccine. 2005;23(17-18):2388-94.
[7]Cuschieri K, Brewster D, Graham C, Nicoll S, Williams A, Murray G, et al. Short report: Influence of HPV type on prognosis in patients diagnosed with invasive cervical cancer. Int J Cancer. 2014;135(11):2721-6.
[8]- Palefsky JM, Holly EA, Ralston ML, Arthur SP, Hogeboom CJ, Darragh TM. Anal cytological abnormalities and anal HPV infection in men with centers for disease control group IV HIV disease. Genitourin Med. 1997;73(3):174-80.
[9]Sugase M, Matsukura T. Distinct manifestations of Human papilloma viruses in the vagina. Int J Cancer. 1997;72(3):412-5.
[10]Rezza G, Giuliani M, Branca M, Benedetto A, Migliore G, Garbuglia AR, et al. Determinants of squamous intraepithelial lesions (SIL) on Pap smear: The role of HPV infection and of HIV-1-induced immunosuppression. DIANAIDS collaborative study group. Eur J Epidemiol. 1997,13(8):937-43.
[11]Kjaer SK, Van Den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, et al. Determinants for genital human papilloma virus (HPV) infection in 1000 randomly chosen young Danish with normal pap smear. Cancer Epidemiol Biomarkers Prev. 1997;6(10):799-805.
[12]McCormack PL, Joura EA. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil): A review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women. Drugs. 2010;70(18):2449-74.
[13]Jabbarpour BM, Esmaeili M, Dastranj A. Oncogenic types of human papillomavirus by Multiplex PCR in cervical cancer lesions in the north west of Iran. Iran J Infect Dis. 2008;13(41):29-34. [Persian]
[14]de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324(1):17-27.
[15]Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirustypes associated with cervical cancer. N Engl J Med. 2003;348(6):518-27.
[16]Mobius G. Cytological early detection of cervical carcinoma: Possibilities and limitations, analysis of failures. J Cancer Res Clin Oncol. 1993;119(9):513-21.
[17]Nikan M, Garshasbi A, Jalali MR, Gilani M, Faghihzadeh S. Detection and typing of human papilloma virus DNA in cervical cancer with In situ hybridization method. J Reprod Infertil. 2000;1(3):18-22.
[18]Ciapponi A, Bardach A, Glujovsky D, Gibbons L, Picconi MA. Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: Systematic review and meta-analysis. PLoS One. 2011;6(10):e25493.
[19]de Mendez MT. Prevalence of human papillomavirus (HPV) genotypes and multiple infections in routine cervical cancer screening in a Spanish regional population. SOJ Microbiol Infect Dis. 2013;1(1):1-6.
[20]Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital wart. Vaccine. 2007;25(16):3001–6.
[21]Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009;5(10):705-19.
[22]Ku CH, Lee SH, Lee SP. Effect of human papillomavirus genotype on severity and prognosis of cervical intraepithelial neoplasia. Obstet Gynecol Sci. 2014;57(1):37-43.
[23]Mahmoudi MM, Hamkar R, Akhavan-Tafti M, Eslamifar A, Adibi L, Sadrabadi AA, et al. Human Papillomavirus Genotyps in cervical cancer in Yazd. Iran J Infect Dis. 2008;12(37):19-24. [Persian]
[24]Allameh T, Moghim S, Farahbod F. Reviewing the Prevalence of Human Papillomavirus (HPV) in Married Women Aged 18-60 Years with Normal Pap Smear and Referring to Gynecology Clinics in Hospitals Affiliated to Isfahan University of Medical Sciences, Iran. J Isfahan Med Sch. 2012;29(163):1-8.
[25]Monsefi N, Dabiri SH, Abbaszadeh M, Safizadeh H, Fotouhi AR, Amirpour RS, et al. Frequency of Dysplastic and Cancerous Pap smear and Genotyping of Human Papillomavirus by DNA Probetechniques in Kerman, Iran. J Kerman Univ Med Sci. 2013;20(5):450-9.
[26]Khodakarami N, Hosseini SJ, Yavari P, Farzaneh F, Etemad K, Salehpour S, et al. Human papillomavirus infection prevalence in women referred to health clinic of Shahid Beheshti university of medical sciences, Tehran, Iran. Iran J Epidemiol. 2012;7(4):35-42.
[2]Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs. 2008;68(3):359-72.
[3]Frazer IH. Development and implementation of papillomavirus prophylactic vaccines. J Immunol. 2014;192(9):4007-11.
[4]Human papillomavirus (HPV) and cervical cancer [internet]. World Health Organization: Comprehensive cervical cancer control: A guide to essential practice. 2014. [updated 2016 Jun; cited 2015 apr]. Available from: http://www.who.int/mediacentre/factsheets/fs380/en/.
[5]Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.
[6]Franco EL, Harper DM. Vaccination against human papillomavirus infection: A new paradigm in cervical cancer control. Vaccine. 2005;23(17-18):2388-94.
[7]Cuschieri K, Brewster D, Graham C, Nicoll S, Williams A, Murray G, et al. Short report: Influence of HPV type on prognosis in patients diagnosed with invasive cervical cancer. Int J Cancer. 2014;135(11):2721-6.
[8]- Palefsky JM, Holly EA, Ralston ML, Arthur SP, Hogeboom CJ, Darragh TM. Anal cytological abnormalities and anal HPV infection in men with centers for disease control group IV HIV disease. Genitourin Med. 1997;73(3):174-80.
[9]Sugase M, Matsukura T. Distinct manifestations of Human papilloma viruses in the vagina. Int J Cancer. 1997;72(3):412-5.
[10]Rezza G, Giuliani M, Branca M, Benedetto A, Migliore G, Garbuglia AR, et al. Determinants of squamous intraepithelial lesions (SIL) on Pap smear: The role of HPV infection and of HIV-1-induced immunosuppression. DIANAIDS collaborative study group. Eur J Epidemiol. 1997,13(8):937-43.
[11]Kjaer SK, Van Den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, et al. Determinants for genital human papilloma virus (HPV) infection in 1000 randomly chosen young Danish with normal pap smear. Cancer Epidemiol Biomarkers Prev. 1997;6(10):799-805.
[12]McCormack PL, Joura EA. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil): A review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women. Drugs. 2010;70(18):2449-74.
[13]Jabbarpour BM, Esmaeili M, Dastranj A. Oncogenic types of human papillomavirus by Multiplex PCR in cervical cancer lesions in the north west of Iran. Iran J Infect Dis. 2008;13(41):29-34. [Persian]
[14]de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324(1):17-27.
[15]Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirustypes associated with cervical cancer. N Engl J Med. 2003;348(6):518-27.
[16]Mobius G. Cytological early detection of cervical carcinoma: Possibilities and limitations, analysis of failures. J Cancer Res Clin Oncol. 1993;119(9):513-21.
[17]Nikan M, Garshasbi A, Jalali MR, Gilani M, Faghihzadeh S. Detection and typing of human papilloma virus DNA in cervical cancer with In situ hybridization method. J Reprod Infertil. 2000;1(3):18-22.
[18]Ciapponi A, Bardach A, Glujovsky D, Gibbons L, Picconi MA. Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: Systematic review and meta-analysis. PLoS One. 2011;6(10):e25493.
[19]de Mendez MT. Prevalence of human papillomavirus (HPV) genotypes and multiple infections in routine cervical cancer screening in a Spanish regional population. SOJ Microbiol Infect Dis. 2013;1(1):1-6.
[20]Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital wart. Vaccine. 2007;25(16):3001–6.
[21]Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009;5(10):705-19.
[22]Ku CH, Lee SH, Lee SP. Effect of human papillomavirus genotype on severity and prognosis of cervical intraepithelial neoplasia. Obstet Gynecol Sci. 2014;57(1):37-43.
[23]Mahmoudi MM, Hamkar R, Akhavan-Tafti M, Eslamifar A, Adibi L, Sadrabadi AA, et al. Human Papillomavirus Genotyps in cervical cancer in Yazd. Iran J Infect Dis. 2008;12(37):19-24. [Persian]
[24]Allameh T, Moghim S, Farahbod F. Reviewing the Prevalence of Human Papillomavirus (HPV) in Married Women Aged 18-60 Years with Normal Pap Smear and Referring to Gynecology Clinics in Hospitals Affiliated to Isfahan University of Medical Sciences, Iran. J Isfahan Med Sch. 2012;29(163):1-8.
[25]Monsefi N, Dabiri SH, Abbaszadeh M, Safizadeh H, Fotouhi AR, Amirpour RS, et al. Frequency of Dysplastic and Cancerous Pap smear and Genotyping of Human Papillomavirus by DNA Probetechniques in Kerman, Iran. J Kerman Univ Med Sci. 2013;20(5):450-9.
[26]Khodakarami N, Hosseini SJ, Yavari P, Farzaneh F, Etemad K, Salehpour S, et al. Human papillomavirus infection prevalence in women referred to health clinic of Shahid Beheshti university of medical sciences, Tehran, Iran. Iran J Epidemiol. 2012;7(4):35-42.